Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
American Journal of Clinical Dermatology
Published in: American Journal of Clinical Dermatology 4/2017

01-08-2017 | Evidence-Based Review

Oral Antibacterial Therapy for Acne Vulgaris: An Evidence-Based Review

Authors: Amanda Bienenfeld, Arielle R. Nagler, Seth J. Orlow

Published in: American Journal of Clinical Dermatology | Issue 4/2017

Login to get access

Abstract

Background

To some degree, acne vulgaris affects nearly every individual worldwide. Oral antibiotic therapy is routinely prescribed for the treatment of moderate to severe inflammatory acne; however, long-term use of oral antibiotics for acne may have unintended consequences.

Objective

The aim of this study was to provide a systematic evaluation of the scientific evidence on the efficacy and appropriate use of oral antibiotics in the treatment of acne.

Methods

A systematic search of MEDLINE was conducted to identify randomized controlled clinical trials, systematic reviews, and meta-analyses evaluating the efficacy of oral antibiotics for acne. Overall, 41 articles that examined oral antibiotics compared with placebo, another oral therapy, topical therapy, alternate dose, or duration were included in this study.

Results

Tetracyclines, macrolides, and trimethoprim/sulfamethoxazole are effective and safe in the treatment of moderate to severe inflammatory acne. Superior efficacy of one type or class of antibiotic could not be determined, therefore the choice of antibiotic is generally based on the side-effect profile. Although different dosing regimens have been studied, there is a lack of standardized comparator trials to determine optimal dosing and duration of each oral antibiotic used in acne. The combination of oral antibiotics with a topical therapy is superior to oral antibiotics alone.

Conclusion

This article provides a systematic evaluation of the scientific evidence of the efficacy of oral antibiotics for acne. Due to heterogeneity in the design of the trials, there is insufficient evidence to support one type, dose, or duration of oral antibiotic over another in terms of efficacy; however, due to increasing resistance to antibiotics, dermatologists should heed consensus guidelines for their appropriate use.
Literature
1.
Tan JK, Bhate K. A global perspective on the epidemiology of acne. Br J Dermatol. 2015;172(Suppl 1):3–12.CrossRefPubMed
2.
3.
Zaenglein AL, Pathy AL, Schlosser BJ, Alikhan A, Baldwin HE, Berson DS, et al. Guidelines of care for the management of acne vulgaris. J Am Acad Dermatol. 2016;74(5):945–73 e33.
4.
Degitz K, Placzek M, Borelli C, Plewig G. Pathophysiology of acne. J Dtsch Dermatol Ges. 2007;5(4):316–23.CrossRefPubMed
5.
6.
Das S, Reynolds RV. Recent advances in acne pathogenesis: implications for therapy. Am J Clin Dermatol. 2014;15(6):479–88.CrossRefPubMed
7.
Beylot C, Auffret N, Poli F, Claudel JP, Leccia MT, Del Giudice P, et al. Propionibacterium acnes: an update on its role in the pathogenesis of acne. J Eur Acad Dermatol Venereol. 2014;28(3):271–8.CrossRefPubMed
8.
Ebell MH, Siwek J, Weiss BD, Woolf SH, Susman JL, Ewigman B, et al. Simplifying the language of evidence to improve patient care: Strength Of Recommendation Taxonomy (SORT): a patient-centered approach to grading evidence in medical literature. J Fam Pract. 2004;53(2):111–20.PubMed
9.
Thiboutot D, Gollnick H, Bettoli V, Dreno B, Kang S, Leyden JJ, et al. New insights into the management of acne: an update from the Global Alliance to Improve Outcomes in Acne group. J Am Acad Dermatol. 2009;60(5 Suppl):S1–50.CrossRefPubMed
10.
Eichenfield LF, Krakowski AC, Piggott C, Del Rosso J, Baldwin H, Friedlander SF, et al. Evidence-based recommendations for the diagnosis and treatment of pediatric acne. Pediatrics. 2013;131(Suppl 3):S163–86.CrossRefPubMed
11.
Goh CL, Abad-Casintahan F, Aw DC, Baba R, Chan LC, Hung NT, et al. South-East Asia study alliance guidelines on the management of acne vulgaris in South-East Asian patients. J Dermatol. 2015;42(10):945–53.CrossRefPubMed
12.
Gollnick HP, Bettoli V, Lambert J, Araviiskaia E, Binic I, Dessinioti C, et al. A consensus-based practical and daily guide for the treatment of acne patients. J Eur Acad Dermatol Venereol. 2016;30(9):1480–90.CrossRefPubMed
13.
Nast A, Dreno B, Bettoli V, Degitz K, Erdmann R, Finlay AY, et al. European evidence-based (S3) guidelines for the treatment of acne. J Eur Acad Dermatol Venereol. 2012;26(Suppl 1):1–29.CrossRefPubMed
14.
Abad-Casintahan F, Chow SK, Goh CL, Kubba R, Miyachi Y, Noppakun N, et al. Toward evidence-based practice in acne: consensus of an Asian Working Group. J Dermatol. 2011;38(11):1041–8.CrossRefPubMed
15.
Gollnick H, Cunliffe W, Berson D, Dreno B, Finlay A, Leyden JJ, et al. Management of acne: a report from a global alliance to improve outcomes in acne. J Am Acad Dermatol. 2003;49(1 Suppl):S1–37.CrossRefPubMed
16.
Dreno B, Bettoli V, Ochsendorf F, Layton A, Mobacken H, Degreef H. European recommendations on the use of oral antibiotics for acne. Eur J Dermatol. 2004;14(6):391–9.PubMed
17.
Monk E, Shalita A, Siegel DM. Clinical applications of non-antimicrobial tetracyclines in dermatology. Pharmacol Res. 2011;63(2):130–45.CrossRefPubMed
18.
Chow AW, Patten V, Guze LB. Comparative susceptibility of anaerobic bacteria to minocycline, doxycycline, and tetracycline. Antimicrob Agents Chemother. 1975;7(1):46–9.CrossRefPubMedPubMedCentral
19.
Pochi PE, Strauss JS. Antibiotic sensitivity of Corynebacterium acnes (Propionibacterium acnes). J Invest Dermatol. 1961;36:423–9.CrossRefPubMed
20.
Marples RR, Kligman AM. Ecological effects of oral antibiotics on the microflora of human skin. Arch Dermatol. 1971;103(2):148–53.CrossRefPubMed
21.
Cunliffe WJ, Forster RA, Greenwood ND, Hetherington C, Holland KT, Holmes RL, et al. Tetracycline and acne vulgaris: a clinical and laboratory investigation. BMJ. 1973;4(5888):332–5.CrossRefPubMedPubMedCentral
22.
Skidmore R, Kovach R, Walker C, Thomas J, Bradshaw M, Leyden J, et al. Effects of subantimicrobial-dose doxycycline in the treatment of moderate acne. Arch Dermatol. 2003;139(4):459–64.CrossRefPubMed
23.
Martin RR, Warr GA, Couch RB, Yeager H, Knight V. Effects of tetracycline on leukotaxis. J Infect Dis. 1974;129(2):110–6.CrossRefPubMed
24.
Esterly NB, Furey NL, Flanagan LE. The effect of antimicrobial agents on leukocyte chemotaxis. J Invest Dermatol. 1978;70(1):51–5.CrossRefPubMed
25.
Cazalis J, Tanabe S, Gagnon G, Sorsa T, Grenier D. Tetracyclines and chemically modified tetracycline-3 (CMT-3) modulate cytokine secretion by lipopolysaccharide-stimulated whole blood. Inflammation. 2009;32(2):130–7.CrossRefPubMed
26.
Ianaro A, Ialenti A, Maffia P, Sautebin L, Rombola L, Carnuccio R, et al. Anti-inflammatory activity of macrolide antibiotics. J Pharmacol Exp Ther. 2000;292(1):156–63.PubMed
27.
Jain A, Sangal L, Basal E, Kaushal GP, Agarwal SK. Anti-inflammatory effects of erythromycin and tetracycline on Propionibacterium acnes induced production of chemotactic factors and reactive oxygen species by human neutrophils. Dermatol Online J. 2002;8(2):2.PubMed
28.
Eady AE, Cove JH, Layton AM. Is antibiotic resistance in cutaneous propionibacteria clinically relevant? Implications of resistance for acne patients and prescribers. Am J Clin Dermatol. 2003;4(12):813–31.CrossRefPubMed
29.
Tan HH. Antibacterial therapy for acne: a guide to selection and use of systemic agents. Am J Clin Dermatol. 2003;4(5):307–14.CrossRefPubMed
30.
31.
Plewig G, Petrozzi JW, Berendes U. Double-blind study of doxycycline in acne vulgaris. Arch Dermatol. 1970;101(4):435–8.CrossRefPubMed
32.
Hersle K, Gisslen H. Minocycline in acne vulgaris: a double-blind study. Curr Ther Res Clin Exp. 1976;19(3):339–42.PubMed
33.
Fleischer AB Jr, Dinehart S, Stough D, Plott RT. Safety and efficacy of a new extended-release formulation of minocycline. Cutis. 2006;78(4 Suppl):21–31.PubMed
34.
Ferahbas A, Utas S, Aykol D, Borlu M, Uksal U. Clinical evaluation of roxithromycin: a double-blind, placebo-controlled and crossover trial in patients with acne vulgaris. J Dermatol. 2004;31(1):6–9.CrossRefPubMed
35.
Hersle K. Trimethoprim-sulphamethoxazole in acne vulgaris. A double-blind study. Dermatologica. 1972;145(3):187–91.CrossRefPubMed
36.
Macdonald RH, Macconnell LE, Dunsmore IR. Trimethoprim-sulphamethoxazole versus placebo in acne vulgaris. Br J Clin Pract. 1972;26(2):97–8.PubMed
37.
Christian GL, Krueger GG. Clindamycin vs placebo as adjunctive therapy in moderately severe acne. Arch Dermatol. 1975;111(8):997–1000.CrossRefPubMed
38.
Simonart T, Dramaix M, De Maertelaer V. Efficacy of tetracyclines in the treatment of acne vulgaris: a review. Br J Dermatol. 2008;158(2):208–16.PubMed
39.
Ozolins M, Eady EA, Avery A, Cunliffe WJ, O’Neill C, Simpson NB, et al. Randomised controlled multiple treatment comparison to provide a cost-effectiveness rationale for the selection of antimicrobial therapy in acne. Health Technol Assess. 2005;9(1):iii–212.
40.
Grosshans E, Belaich S, Meynadier J, Alirezai M, Thomas L. A comparison of the efficacy and safety of lymecycline and minocycline in patients with moderately severe acne vulgaris. Eur J Dermatol. 1998;8(3):161–6.PubMed
41.
Bossuyt L, Bosschaert J, Richert B, Cromphaut P, Mitchell T, Al Abadie M, et al. Lymecycline in the treatment of acne: an efficacious, safe and cost-effective alternative to minocycline. Eur J Dermatol. 2003;13(2):130–5.PubMed
42.
Garner SE, Eady A, Bennett C, Newton JN, Thomas K, Popescu CM. Minocycline for acne vulgaris: efficacy and safety. Cochrane Database Syst Rev. 2012;(8):CD002086.
43.
Babaeinejad S, Khodaeiani E, Fouladi RF. Comparison of therapeutic effects of oral doxycycline and azithromycin in patients with moderate acne vulgaris: what is the role of age? J Dermatol Treat. 2011;22(4):206–10.CrossRef
44.
Kus S, Yucelten D, Aytug A. Comparison of efficacy of azithromycin vs. doxycycline in the treatment of acne vulgaris. Clin Exp Dermatol. 2005;30(3):215–20.CrossRefPubMed
45.
Maleszka R, Turek-Urasinska K, Oremus M, Vukovic J, Barsic B. Pulsed azithromycin treatment is as effective and safe as 2-week-longer daily doxycycline treatment of acne vulgaris: a randomized, double-blind, noninferiority study. Skinmed. 2011;9(2):86–94.PubMed
46.
Hayashi N, Kawashima M. Efficacy of oral antibiotics on acne vulgaris and their effects on quality of life: a multicenter randomized controlled trial using minocycline, roxithromycin and faropenem. J Dermatol. 2011;38(2):111–9.CrossRefPubMed
47.
Gammon WR, Meyer C, Lantis S, Shenefelt P, Reizner G, Cripps DJ. Comparative efficacy of oral erythromycin versus oral tetracycline in the treatment of acne vulgaris. A double-blind study. J Am Acad Dermatol. 1986;14(2 Pt 1):183–6.
48.
Gibson JR, Darley CR, Harvey SG, Barth J. Oral trimethoprim versus oxytetracycline in the treatment of inflammatory acne vulgaris. Br J Dermatol. 1982;107(2):221–4.CrossRefPubMed
49.
50.
Leyden JJ, Bruce S, Lee CS, Ling M, Sheth PB, Stewart DM, et al. A randomized, phase 2, dose-ranging study in the treatment of moderate to severe inflammatory facial acne vulgaris with doxycycline calcium. J Drugs Dermatol. 2013;12(6):658–63.PubMed
51.
Moore A, Ling M, Bucko A, Manna V, Rueda MJ. Efficacy and safety of subantimicrobial dose, modified-release doxycycline 40 mg versus doxycycline 100 mg versus placebo for the treatment of inflammatory lesions in moderate and severe acne: a randomized, double-blinded, controlled study. J Drugs Dermatol. 2015;14(6):581–6.PubMed
52.
Toossi P, Farshchian M, Malekzad F, Mohtasham N, Kimyai-Asadi A. Subantimicrobial-dose doxycycline in the treatment of moderate facial acne. J Drugs Dermatol. 2008;7(12):1149–52.PubMed
53.
Del Rosso JQ. A status report on the use of subantimicrobial-dose doxycycline: a review of the biologic and antimicrobial effects of the tetracyclines. Cutis. 2004;74(2):118–22.PubMed
54.
Walker C, Thomas J, Nango S, Lennon J, Wetzel J, Powala C. Long-term treatment with subantimicrobial dose doxycycline exerts no antibacterial effect on the subgingival microflora associated with adult periodontitis. J Periodontol. 2000;71(9):1465–71.CrossRefPubMed
55.
Thomas J, Walker C, Bradshaw M. Long-term use of subantimicrobial dose doxycycline does not lead to changes in antimicrobial susceptibility. J Periodontol. 2000;71(9):1472–83.CrossRefPubMed
56.
McKeage K, Deeks ED. Doxycycline 40 mg capsules (30 mg immediate-release/10 mg delayed-release beads): anti-inflammatory dose in rosacea. Am J Clin Dermatol. 2010;11(3):217–22.CrossRefPubMed
57.
Pierard-Franchimont C, Goffin V, Arrese JE, Martalo O, Braham C, Slachmuylders P, et al. Lymecycline and minocycline in inflammatory acne: a randomized, double-blind intent-to-treat study on clinical and in vivo antibacterial efficacy. Skin Pharmacol Appl Skin Physiol. 2002;15(2):112–9.CrossRefPubMed
58.
Stewart DM, Torok HM, Weiss JS, Plott RT. Dose-ranging efficacy of new once-daily extended-release minocycline for acne vulgaris. Cutis. 2006;78(4 Suppl):11–20.PubMed
59.
Dubertret L, Alirezai M, Rostain G, Lahfa M, Forsea D, Niculae BD, et al. The use of lymecycline in the treatment of moderate to severe acne vulgaris: a comparison of the efficacy and safety of two dosing regimens. Eur J Dermatol. 2003;13(1):44–8.PubMed
60.
Basta-Juzbasic A, Lipozencic J, Oremovic L, Kotrulja L, Gruber F, Brajac I, et al. Acta dose-finding study of azithromycin in the treatment of acne vulgaris. Acta Dermatovenerol Croat. 2007;15(3):141–7.PubMed
61.
Lee YH, Liu G, Thiboutot DM, Leslie DL, Kirby JS. A retrospective analysis of the duration of oral antibiotic therapy for the treatment of acne among adolescents: investigating practice gaps and potential cost-savings. J Am Acad Dermatol. 2014;71(1):70–6.CrossRefPubMed
62.
Straight CE, Lee YH, Liu G, Kirby JS. Duration of oral antibiotic therapy for the treatment of adult acne: a retrospective analysis investigating adherence to guideline recommendations and opportunities for cost-savings. J Am Acad Dermatol. 2015;72(5):822–7.CrossRefPubMed
63.
Nagler AR, Milam EC, Orlow SJ. The use of oral antibiotics before isotretinoin therapy in patients with acne. J Am Acad Dermatol. 2016;74(2):273–9.CrossRefPubMed
64.
Blaney DJ, Cook CH. Topical use of tetracycline in the treatment of acne: a double-blind study comparing topical and oral tetracycline therapy and placebo. Arch Dermatol. 1976;112(7):971–3.CrossRefPubMed
65.
Smith JG Jr, Chalker DK, Wehr RF. The effectiveness of topical and oral tetracycline for acne. South Med J. 1976;69(6):695–7.CrossRefPubMed
66.
Braathen LR. Topical clindamycin versus oral tetracycline and placebo in acne vulgaris. Scand J Infect Dis Suppl. 1984;43:71–5.PubMed
67.
Gratton D, Raymond GP, Guertin-Larochelle S, Maddin SW, Leneck CM, Warner J, et al. Topical clindamycin versus systemic tetracycline in the treatment of acne. Results of a multiclinic trial. J Am Acad Dermatol. 1982;7(1):50–3.CrossRefPubMed
68.
Rapaport M, Puhvel SM, Reisner RM. Evaluation of topical erythromycin and oral tetracycline in acne vulgaris. Cutis. 1982;30(1):122–6, 30, 32–5.
69.
Katsambas A, Towarky AA, Stratigos J. Topical clindamycin phosphate compared with oral tetracycline in the treatment of acne vulgaris. Br J Dermatol. 1987;116(3):387–91.CrossRefPubMed
70.
Sheehan-Dare RA, Papworth-Smith J, Cunliffe WJ. A double-blind comparison of topical clindamycin and oral minocycline in the treatment of acne vulgaris. Acta Derm Venereol. 1990;70(6):534–7.PubMed
71.
Norris JF, Hughes BR, Basey AJ, Cunliffe WJ. A comparison of the effectiveness of topical tetracycline, benzoyl-peroxide gel and oral oxytetracycline in the treatment of acne. Clin Exp Dermatol. 1991;16(1):31–3.CrossRefPubMed
72.
Thiboutot DM, Shalita AR, Yamauchi PS, Dawson C, Arsonnaud S, Kang S. Combination therapy with adapalene gel 0.1% and doxycycline for severe acne vulgaris: a multicenter, investigator-blind, randomized, controlled study. Skinmed. 2005;4(3):138–46.CrossRefPubMed
73.
Hayashi N, Kawashima M. Multicenter randomized controlled trial on combination therapy with 0.1% adapalene gel and oral antibiotics for acne vulgaris: comparison of the efficacy of adapalene gel alone and in combination with oral faropenem. J Dermatol. 2012;39(6):511–5.CrossRefPubMed
74.
Cunliffe WJ, Meynadier J, Alirezai M, George SA, Coutts I, Roseeuw DI, et al. Is combined oral and topical therapy better than oral therapy alone in patients with moderate to moderately severe acne vulgaris? A comparison of the efficacy and safety of lymecycline plus adapalene gel 0.1%, versus lymecycline plus gel vehicle. J Am Acad Dermatol. 2003;49(3 Suppl):S218–26.
75.
Tan J, Stein Gold L, Schlessinger J, Brodell R, Jones T, Cruz A, et al. Short-term combination therapy and long-term relapse prevention in the treatment of severe acne vulgaris. J Drugs Dermatol. 2012;11(2):174–80.PubMed
76.
Gold LS, Cruz A, Eichenfield L, Tan J, Jorizzo J, Kerrouche N, et al. Effective and safe combination therapy for severe acne vulgaris: a randomized, vehicle-controlled, double-blind study of adapalene 0.1%-benzoyl peroxide 2.5% fixed-dose combination gel with doxycycline hyclate 100 mg. Cutis. 2010;85(2):94–104.PubMed
77.
Dreno B, Kaufmann R, Talarico S, Torres Lozada V, Rodriguez-Castellanos MA, Gomez-Flores M, et al. Combination therapy with adapalene-benzoyl peroxide and oral lymecycline in the treatment of moderate to severe acne vulgaris: a multicentre, randomized, double-blind controlled study. Br J Dermatol. 2011;165(2):383–90.CrossRefPubMed
78.
Antibiotic resistance threats in the United States, 2013. Centers for Disease Control and Prevention; 2013.
79.
Ross JI, Snelling AM, Carnegie E, Coates P, Cunliffe WJ, Bettoli V, et al. Antibiotic-resistant acne: lessons from Europe. Br J Dermatol. 2003;148(3):467–78.CrossRefPubMed
80.
Walsh TR, Efthimiou J, Dréno B. Systematic review of antibiotic resistance in acne: an increasing topical and oral threat. Lancet Infect Dis. 2016;16(3):e23–33.CrossRefPubMed
81.
Eady EA, Cove JH, Holland KT, Cunliffe WJ. Erythromycin resistant propionibacteria in antibiotic treated acne patients: association with therapeutic failure. Br J Dermatol. 1989;121(1):51–7.CrossRefPubMed
82.
Leyden JJ, McGinley KJ, Cavalieri S, Webster GF, Mills OH, Kligman AM. Propionibacterium acnes resistance to antibiotics in acne patients. J Am Acad Dermatol. 1983;8(1):41–5.CrossRefPubMed
83.
Levy RM, Huang EY, Roling D, Leyden JJ, Margolis DJ. Effect of antibiotics on the oropharyngeal flora in patients with acne. Arch Dermatol. 2003;139(4):467–71.CrossRefPubMed
84.
Adams SJ, Cunliffe WJ, Cooke EM. Long-term antibiotic therapy for acne vulgaris: effects on the bowel flora of patients and their relatives. J Invest Dermatol. 1985;85(1):35–7.CrossRefPubMed
85.
Patel M, Bowe WP, Heughebaert C, Shalita AR. The development of antimicrobial resistance due to the antibiotic treatment of acne vulgaris: a review. J Drugs Dermatol. 2010;9(6):655–64.PubMed
86.
Margolis DJ, Bowe WP, Hoffstad O, Berlin JA. Antibiotic treatment of acne may be associated with upper respiratory tract infections. Arch Dermatol. 2005;141(9):1132–6.CrossRefPubMed
87.
Margolis DJ, Fanelli M, Kupperman E, Papadopoulos M, Metlay JP, Xie SX, et al. Association of pharyngitis with oral antibiotic use for the treatment of acne: a cross-sectional and prospective cohort study. Arch Dermatol. 2012;148(3):326–32.CrossRefPubMed
88.
Margolis DJ, Fanelli M, Hoffstad O, Lewis JD. Potential association between the oral tetracycline class of antimicrobials used to treat acne and inflammatory bowel disease. Am J Gastroenterol. 2010;105(12):2610–6.CrossRefPubMed
Metadata
Title
Oral Antibacterial Therapy for Acne Vulgaris: An Evidence-Based Review
Authors
Amanda Bienenfeld
Arielle R. Nagler
Seth J. Orlow
Publication date
01-08-2017
Publisher
Springer International Publishing
Published in
American Journal of Clinical Dermatology / Issue 4/2017
Print ISSN: 1175-0561
Electronic ISSN: 1179-1888
DOI
https://doi.org/10.1007/s40257-017-0267-z

Other articles of this Issue 4/2017

American Journal of Clinical Dermatology 4/2017 Go to the issue

Erratum

Erratum to: Calcipotriol Plus Betamethasone Dipropionate Aerosol Foam in Patients with Moderate-to-Severe Psoriasis: Sub-Group Analysis of the PSO-ABLE Study

Review Article

PAPA, PASH and PAPASH Syndromes: Pathophysiology, Presentation and Treatment

Letter to the Editor

Comment on: Facial Hyperpigmentation in Skin of Color: Special Considerations and Treatment

Systematic Review

Treatment of Porokeratosis: A Systematic Review

Original Research Article

Development and Validation of a Novel Questionnaire for Adherence with Topical Treatments in Psoriasis (QATOP)

Letter to the Editor

Author’s Reply to Cohen: Facial Hyperpigmentation in Skin of Color: Special Considerations and Treatment